about
Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.Blocking of the Ubiquitin-Proteasome System Prevents Inflammation-Induced Bone Loss by Accelerating M-CSF Receptor c-Fms Degradation in Osteoclast Differentiation.The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio.
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Current treatment options for myeloma.
@ast
Current treatment options for myeloma.
@en
type
label
Current treatment options for myeloma.
@ast
Current treatment options for myeloma.
@en
prefLabel
Current treatment options for myeloma.
@ast
Current treatment options for myeloma.
@en
P2093
P2860
P1476
Current treatment options for myeloma.
@en
P2093
Amin Rahemtulla
Evangelos Terpos
Meletios-Athanassios Dimopoulos
P2860
P304
P356
10.1517/14656566.6.7.1127
P407
P577
2005-06-01T00:00:00Z